Is NewAmsterdam Pharma Company N.V. (NAMS) a Buy, Sell, or Hold?
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
$32.2605 USD
-$1.03 (-3.09%)
- Volume
- 342.1K
- Average Volume
- 1.3M
- Market Capitalization
- $3.77B
- P/E Ratio
- -17.82
- Dividend Yield
- 0.00%
- Price Target
- $48.00
- Year High
- $42.21
- Year Low
- $20.53
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $9.76
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Michael Davidson |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | NAMS |
| CUSIP | N62P1A109 |
| CIK | 0001936258 |
| Web | https://www.newamsterdampharma.com |
| Phone | 31 35 206 2971 |
| Currency | USD |
| Employees | 100 |
| Country | NL |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 9.76 |
| Quick Ratio | 9.76 |
| Cash Ratio | 6.79 |
Sales & Book Value
| Annual Sales | $22.5M |
| Price / Sales | 167.13 |
| Cash Flow | -1.17 |
| Price / Cash Flow | -26.52 |
| Price / Book | 5.87 |
Price Target and Rating
| Average Stock Price Forecast | $48.00 |
| High Stock Price Forecast | $51.00 |
| Low Stock Price Forecast | $45.00 |
| Forecast Upside/Downside | -32.79% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 10 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.75 |
| Trailing P/E Ratio | -17.82 |
| PEG Ratio | 2.97 |
| P/E Growth | 2.97 |
| Net Income | $-203.82M |
| Net Margin | -942.76% |
| Pretax Margin | -942.76% |
| Return on Equity | -29.80% |
| Return on Assets | -29.04% |
Financials Score
| AltmanZ Score | 33.11 |
| Piotroski Score | 1.00 |
| Working Capital | 590.62M |
| Total Assets | 732.64M |
| Ebit | -212.73M |
| Market Cap | 3.89B |
| Total Liabilities | 67.42M |
Poll Results
About NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Stock
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. ...
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 16:01:00
NAARDEN, The Netherlands and MIAMI, July 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 28,700 of NewAmsterdam's ordinary shares to four non-executive new hires.
2026-07-01 08:00:00
NAARDEN, the Netherlands and MIAMI, July 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for the prevention of early Alzheimer's disease, at the Alzheimer's Association International Conference (AAIC) 2026, taking place on July 12 – 15, 2026 in London, United Kingdom.
2026-06-10 00:52:09
NewAmsterdam Pharma Company N.V. (NAMS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
2026-06-03 08:00:00
NAARDEN, The Netherlands and MIAMI, June 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the National Lipid Association (NLA) 2026 Scientific Sessions, taking place on June 11 – 14, 2026 in Chicago, Illinois.
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
2026-05-28 08:00:00
NAARDEN, the Netherlands and MIAMI, May 28, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:
2026-05-13 15:00:51
NewAmsterdam Pharma Company N.V. (NAMS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May
2026-05-11 08:41:00
NAARDEN, the Netherlands and MIAMI, May 11, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:
2026-05-09 20:03:52
NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial Transcript
Frequently Asked Questions
-
What is the current NewAmsterdam Pharma Company N.V. (NAMS) stock price?
-
NewAmsterdam Pharma Company N.V.(NASDAQ:NAMS) stock price is $32.2605 in the last trading session. During the trading session, NAMS stock reached the peak price of $42.205 while $20.529 was the lowest point it dropped to. The percentage change in NAMS stock occurred in the recent session was --3.09% while the dollar amount for the price change in NAMS stock was -$-1.03.
-
NAMS's industry and sector of operation?
-
The NASDAQ listed NAMS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of NAMS?
-
Marc Ditmarsch | Chief Development Officer
Chris Deluzio | Executive Vice President of Sales Enterprise Operations
Douglas F. Kling | Chief Operating Officer
Louise Kooij | Chief Accounting Officer
Juliette Audet | Chief Strategy & Business Officer -
How many employees does NAMS have?
-
Number of NAMS employees currently stands at 100. NAMS operates from Gooimeer 2-35, Naarden, NH 1411 DC, NL.
-
Link for NAMS official website?
-
Official Website of NAMS is: https://www.newamsterdampharma.com
-
How do I contact NAMS?
-
NAMS could be contacted at phone #31 35 206 2971 and can also be accessed through its website. NAMS operates from Gooimeer 2-35, Naarden, NH 1411 DC, NL.
-
How many shares of NAMS are traded daily?
-
The average number of NAMS shares traded daily for last 3 months was 1.3M.
-
What is the market cap of NAMS currently?
-
The market value of NAMS currently stands at $3.77B with its latest stock price at $32.2605